AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
Read Moreby Selina McKee | Nov 8, 2018 | News | 0
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
Read Moreby Selina McKee | Nov 1, 2018 | News | 0
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic competition for one of its key products.
Read Moreby Selina McKee | Nov 10, 2016 | News | 0
AstraZeneca’s third-quarter net profit came in at 32 percent higher than a year ago, as a substantial one-time tax gain and currency exchange benefit helped weather falling sales during the period.
Read Moreby Selina McKee | Oct 27, 2016 | News | 0
GlaxoSmithKline has posted a 23 percent leap in sales to £7.5 billion for the third quarter, while core operating profit jumped 35 percent to £2.3 billion, beating expectations.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
